312 related articles for article (PubMed ID: 32239659)
1. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study.
Cahn A; Raz I; Bonaca M; Mosenzon O; Murphy SA; Yanuv I; Rozenberg A; Wilding JPH; Bhatt DL; McGuire DK; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Jermendy G; Hadjadj S; Langkilde AM; Sabatine MS; Wiviott SD; Leiter LA
Diabetes Obes Metab; 2020 Aug; 22(8):1357-1368. PubMed ID: 32239659
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Jabbour S; Seufert J; Scheen A; Bailey CJ; Karup C; Langkilde AM
Diabetes Obes Metab; 2018 Mar; 20(3):620-628. PubMed ID: 28950419
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
Cahn A; Mosenzon O; Wiviott SD; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
Diabetes Care; 2020 Feb; 43(2):468-475. PubMed ID: 31843945
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Furtado RHM; Raz I; Goodrich EL; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Aylward P; Dalby AJ; Dellborg M; Dimulescu D; Nicolau JC; Oude Ophuis AJM; Cahn A; Mosenzon O; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2022 May; 145(21):1581-1591. PubMed ID: 35510542
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Ptaszynska A; Johnsson KM; Parikh SJ; de Bruin TW; Apanovitch AM; List JF
Drug Saf; 2014 Oct; 37(10):815-29. PubMed ID: 25096959
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Fioretto P; Mansfield TA; Ptaszynska A; Yavin Y; Johnsson E; Parikh S
Drugs Aging; 2016 Jul; 33(7):511-22. PubMed ID: 27357173
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Zelniker TA; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS;
N Engl J Med; 2019 Jan; 380(4):347-357. PubMed ID: 30415602
[TBL] [Abstract][Full Text] [Related]
8. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Bansilal S; Bhatt DL; Leiter LA; McGuire DK; Wilding JP; Gause-Nilsson IA; Langkilde AM; Johansson PA; Sabatine MS
Am Heart J; 2018 Jun; 200():83-89. PubMed ID: 29898853
[TBL] [Abstract][Full Text] [Related]
9. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
[TBL] [Abstract][Full Text] [Related]
10. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
12. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
13. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
[TBL] [Abstract][Full Text] [Related]
14. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
[TBL] [Abstract][Full Text] [Related]
15. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
Kohler S; Salsali A; Hantel S; Kaspers S; Woerle HJ; Kim G; Broedl UC
Clin Ther; 2016 Jun; 38(6):1299-1313. PubMed ID: 27085585
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.
Yang W; Ji L; Zhou Z; Cain VA; Johnsson KM; Sjöström CD
J Diabetes; 2017 Aug; 9(8):787-799. PubMed ID: 27625142
[TBL] [Abstract][Full Text] [Related]
17. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Cahn A; Wiviott SD; Mosenzon O; Murphy SA; Goodrich EL; Yanuv I; Rozenberg A; Wilding JPH; Leiter LA; Bhatt DL; McGuire DK; Litwak L; Kooy A; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Raz I
Diabetes Obes Metab; 2021 Jan; 23(1):29-38. PubMed ID: 32844557
[TBL] [Abstract][Full Text] [Related]
18. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
Johnsson K; Johnsson E; Mansfield TA; Yavin Y; Ptaszynska A; Parikh SJ
Postgrad Med; 2016 May; 128(4):346-55. PubMed ID: 26878357
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Yang W; Han P; Min KW; Wang B; Mansfield T; T'Joen C; Iqbal N; Johnsson E; Ptaszynska A
J Diabetes; 2016 Nov; 8(6):796-808. PubMed ID: 26589253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
